Immunotherapy Archives

April 9, 2025

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.

February 20, 2025

Promising Results in Difficult-to-Treat CLL with Epcoritamab

Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.

October 23, 2024

Solid Results for Epcoritimab for Relapsed / Refractory CLL

Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.

July 25, 2024

Long-term Outcomes After Lenalidomide plus Rituximab for CLL

With the introduction of BTK inhibitors to treat CLL, there has been no disparity in survival outcomes for patients of different races and ethnicities.

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

March 21, 2022

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.

January 18, 2022

ASH 2021: Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

This research was presented by Dr. Arnon Kater and colleagues at the American Society for Hematology annual meeting which was held December 2021 (ASH 2021).

December 4, 2020

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

Also during ASH 2019, Dr. Koffman interviewed Dr. Adrian Wiestner, who discussed bi-specific antibodies to improve the immune system in CLL patients. There is reason to believe that when used in combination with a BTK inhibitor such as ibrutinib, they would have increased effectiveness, as ibrutinib improves T cell

December 4, 2020

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

Dr. Brian Koffman interviewed Dr. Krish Patel at ASH 2019, about how our native immune system is excellent at controlling cancer when it is working normally. In CLL, the immune system has become dysregulated and does a poor job controlling cancer. Could modifying the immune system with off-the-shelf bi-specific

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Immunotherapy

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Promising Results in Difficult-to-Treat CLL with Epcoritamab

Solid Results for Epcoritimab for Relapsed / Refractory CLL

Long-term Outcomes After Lenalidomide plus Rituximab for CLL

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

ASH 2021: Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT